Antibodies Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

Description

According to a recent report by Fairfield Market Research, the global antibody contract manufacturing market is set to achieve remarkable growth over the next decade, expanding from $6.3 billion in 2024 to an estimated $13.6 billion by 2031. This expansion is driven by a robust compound annual growth rate (CAGR) of 11.6%, reflecting the increasing demand for biopharmaceuticals and advancements in biotechnology.

Market Overview and Growth Catalysts

The antibody contract manufacturing market, valued at $4.8 billion in 2022, has experienced consistent growth. From 2016 to 2022, the market saw a historical CAGR of 9.6%. This upward trend is expected to continue, propelled by the rising prevalence of chronic and infectious diseases and significant advancements in biotechnology.

Dominance of Monoclonal Antibodies

Renowned for their specificity and efficacy in treating various diseases, including cancer and autoimmune disorders, mAbs are integral to the biopharmaceutical industry. Their standardized production process ensures consistency and quality, making them a preferred choice for contract manufacturing.

Advancements in Continuous Manufacturing

A notable trend in the market is the adoption of end-to-end continuous manufacturing processes. This innovative approach promises to revolutionize biologics production by reducing manufacturing time, lowering costs, and minimizing contamination risks. Continuous production methods, with real-time quality monitoring, ensure high reliability in the final products. Although initial investments are substantial, the long-term benefits of continuous manufacturing are significant.

Regional Insights

United States: Innovation Leader

The United States led the North American market, holding about 89.4% of the market share in 2022. The country's advanced healthcare infrastructure, robust clinical trial pipeline, and strong governmental support for biologics drive market growth. The rapid development and approval of antibody drugs, particularly during the COVID-19 pandemic, have further bolstered the market.

United Kingdom: R&D Powerhouse

The United Kingdom accounted for around 26.7% of the European market in 2022, driven by substantial investments in research and development for infectious diseases. A strong regulatory framework and public sector funding are crucial factors supporting market growth. The U.K. remains pivotal in global efforts to combat neglected and infectious diseases through innovative antibody therapies.

South Korea: Emerging Leader

South Korea emerged as a significant player in the East Asian market, capturing approximately 70.6% of the market share in 2022. The country's commitment to biopharmaceutical manufacturing excellence, highlighted by events like the Biologics Manufacturing Korea conference, positions it as a key hub for antibody contract manufacturing. Recognitions such as the Korea Bioprocessing Excellence Award underscore South Korea's capabilities in this sector.

Market Segmentation

Product and Expression Systems

Monoclonal antibodies dominated the product segment, holding approximately 89.1% of the market share in 2022. The mammalian expression system, favored for its ability to produce complex proteins with human-like post-translational modifications, accounted for about 84.4% of the market.

Company Size and Scale of Operations

Mid-sized companies represented around 46.2% of the market in 2022. These companies are increasingly driving innovation and securing approvals for new drugs, despite often lacking in-house manufacturing capabilities. Commercial scale operations held a 54.4% share, driven by the high incidence of chronic diseases and the growing need for contract manufacturing to meet global demand.

Competitive Landscape

The antibody contract manufacturing market is characterized by significant consolidation, with major players pursuing mergers and acquisitions to enhance their capabilities. Notable developments include:

AMRI's Acquisition: In June 2017, AMRI was acquired in a deal valued at over $920 million, reflecting the active M&A market for contract manufacturers.
AGC Biologics and Ono Pharmaceutical Partnership: In August 2020, AGC Biologics partnered with Ono Pharmaceutical Co., Ltd. to develop innovative biopharmaceuticals, showcasing the industry's collaborative efforts to advance drug development.

Key Market Players Include

AMRI
AGC Biologics
Aldevron
Eurofins CDMO
Boehringer Ingelheim BioXcellence
FUJIFILM Diosynth Biotechnologies
Emergent BioSolutions
KBI Biopharma
Lonza
Novasep
Nitto Avecia Pharma Services
Pierre Fabre
Samsung BioLogics
Synthon
Thermo Fisher Scientific
AbbVie, Inc.

Global Antibodies Contract Manufacturing Market Segmentation

By Product:

Monoclonal Antibodies
Antibody Fragments
Polyclonal Antibodies

By Expression System:

Mammalian
Microbial
- Bacteria
- Yeast

By Company Size:

Small
Mid-sized
Large
Very large

By Scale of Operation:

Preclinical
Clinical
Commercial

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Antibodies Contract Manufacturing Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Product Adoption/Usage Analysis
2.4. List of Trading Companies
2.5. List of Local Manufacturers and their Distribution Strategy/Locations
2.6. Key Regulatory Scenario
2.7. Value Chain Analysis
2.8. Porter's Five Forces Analysis
2.9. COVID-19 Impact Analysis
- 2.9.1. Supply
- 2.9.2. Demand
2.10. Economic Overview
- 2.10.1. World Economic Projections 2.11.PESTLE Analysis

3. Global Antibodies Contract Manufacturing Market Outlook, 2018 - 2031

3.1. Global Antibodies Contract Manufacturing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Monoclonal Antibodies
  - 3.1.1.2. Antibody Fragments
  - 3.1.1.3. Polyclonal Antibodies
3.2. Global Antibodies Contract Manufacturing Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Mammalian
  - 3.2.1.2. Microbial
    - 3.2.1.2.1. Bacteria
    - 3.2.1.2.2. Yeast
3.3. Global Antibodies Contract Manufacturing Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Small
  - 3.3.1.2. Mid-sized
  - 3.3.1.3. Large
  - 3.3.1.4. Very large
3.4. Global Antibodies Contract Manufacturing Market Outlook, by Scale of Operation, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. Preclinical
  - 3.4.1.2. Clinical
  - 3.4.1.3. Commercial
3.5. Global Antibodies Contract Manufacturing Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.5.1. Key Highlights
  - 3.5.1.1. North America
  - 3.5.1.2. Europe
  - 3.5.1.3. Asia Pacific
  - 3.5.1.4. Latin America
  - 3.5.1.5. Middle East & Africa

4. North America Antibodies Contract Manufacturing Market Outlook, 2018 - 2031

4.1. North America Antibodies Contract Manufacturing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Monoclonal Antibodies
  - 4.1.1.2. Antibody Fragments
  - 4.1.1.3. Polyclonal Antibodies
4.2. North America Antibodies Contract Manufacturing Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Mammalian
  - 4.2.1.2. Microbial
    - 4.2.1.2.1. Bacteria
    - 4.2.1.2.2. Yeast
4.3. North America Antibodies Contract Manufacturing Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Small
  - 4.3.1.2. Mid-sized
  - 4.3.1.3. Large
  - 4.3.1.4. Very large
4.4. North America Antibodies Contract Manufacturing Market Outlook, by Scale of Operation, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. Preclinical
  - 4.4.1.2. Clinical
  - 4.4.1.3. Commercial
- 4.4.2. BPS Analysis/Market Attractiveness Analysis
4.5. North America Antibodies Contract Manufacturing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.5.1. Key Highlights
  - 4.5.1.1. U.S. Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 4.5.1.2. U.S. Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 4.5.1.3. U.S. Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 4.5.1.4. U.S. Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 4.5.1.5. Canada Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 4.5.1.6. Canada Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 4.5.1.7. Canada Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 4.5.1.8. Canada Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
- 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Antibodies Contract Manufacturing Market Outlook, 2018 - 2031

5.1. Europe Antibodies Contract Manufacturing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Monoclonal Antibodies
  - 5.1.1.2. Antibody Fragments
  - 5.1.1.3. Polyclonal Antibodies
5.2. Europe Antibodies Contract Manufacturing Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Mammalian
  - 5.2.1.2. Microbial
    - 5.2.1.2.1. Bacteria
    - 5.2.1.2.2. Yeast
5.3. Europe Antibodies Contract Manufacturing Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Small
  - 5.3.1.2. Mid-sized
  - 5.3.1.3. Large
  - 5.3.1.4. Very large
5.4. Europe Antibodies Contract Manufacturing Market Outlook, by Scale of Operation, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Preclinical
  - 5.4.1.2. Clinical
  - 5.4.1.3. Commercial
- 5.4.2. BPS Analysis/Market Attractiveness Analysis
5.5. Europe Antibodies Contract Manufacturing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.5.1. Key Highlights
  - 5.5.1.1. Germany Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.5.1.2. Germany Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 5.5.1.3. Germany Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 5.5.1.4. Germany Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 5.5.1.5. U.K. Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.5.1.6. U.K. Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 5.5.1.7. U.K. Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 5.5.1.8. U.K. Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 5.5.1.9. France Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.5.1.10. France Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 5.5.1.11. France Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 5.5.1.12. France Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 5.5.1.13. Italy Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.5.1.14. Italy Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 5.5.1.15. Italy Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 5.5.1.16. Italy Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 5.5.1.17. Turkey Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.5.1.18. Turkey Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 5.5.1.19. Turkey Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 5.5.1.20. Turkey Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 5.5.1.21. Russia Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.5.1.22. Russia Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 5.5.1.23. Russia Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 5.5.1.24. Russia Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 5.5.1.25. Rest of Europe Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 5.5.1.26. Rest of Europe Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 5.5.1.27. Rest of Europe Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 5.5.1.28. Rest of Europe Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
- 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Antibodies Contract Manufacturing Market Outlook, 2018 - 2031

6.1. Asia Pacific Antibodies Contract Manufacturing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Monoclonal Antibodies
  - 6.1.1.2. Antibody Fragments
  - 6.1.1.3. Polyclonal Antibodies
6.2. Asia Pacific Antibodies Contract Manufacturing Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Mammalian
  - 6.2.1.2. Microbial
    - 6.2.1.2.1. Bacteria
    - 6.2.1.2.2. Yeast
6.3. Asia Pacific Antibodies Contract Manufacturing Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Small
  - 6.3.1.2. Mid-sized
  - 6.3.1.3. Large
  - 6.3.1.4. Very large
6.4. Asia Pacific Antibodies Contract Manufacturing Market Outlook, by Scale of Operation, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. Preclinical
  - 6.4.1.2. Clinical
  - 6.4.1.3. Commercial
- 6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. Asia Pacific Antibodies Contract Manufacturing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.5.1. Key Highlights
  - 6.5.1.1. China Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.5.1.2. China Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 6.5.1.3. China Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 6.5.1.4. China Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 6.5.1.5. Japan Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.5.1.6. Japan Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 6.5.1.7. Japan Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 6.5.1.8. Japan Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 6.5.1.9. South Korea Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.5.1.10. South Korea Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 6.5.1.11. South Korea Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 6.5.1.12. South Korea Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 6.5.1.13. India Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.5.1.14. India Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 6.5.1.15. India Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 6.5.1.16. India Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 6.5.1.17. Southeast Asia Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.5.1.18. Southeast Asia Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 6.5.1.19. Southeast Asia Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 6.5.1.20. Southeast Asia Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 6.5.1.21. Rest of Asia Pacific Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 6.5.1.22. Rest of Asia Pacific Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 6.5.1.23. Rest of Asia Pacific Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 6.5.1.24. Rest of Asia Pacific Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
- 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Antibodies Contract Manufacturing Market Outlook, 2018 - 2031

7.1. Latin America Antibodies Contract Manufacturing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Monoclonal Antibodies
  - 7.1.1.2. Antibody Fragments
  - 7.1.1.3. Polyclonal Antibodies
7.2. Latin America Antibodies Contract Manufacturing Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Mammalian
  - 7.2.1.2. Microbial
    - 7.2.1.2.1. Bacteria
    - 7.2.1.2.2. Yeast
7.3. Latin America Antibodies Contract Manufacturing Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Small
  - 7.3.1.2. Mid-sized
  - 7.3.1.3. Large
  - 7.3.1.4. Very large
7.4. Latin America Antibodies Contract Manufacturing Market Outlook, by Scale of Operation, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Preclinical
  - 7.4.1.2. Clinical
  - 7.4.1.3. Commercial
- 7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Latin America Antibodies Contract Manufacturing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.5.1. Key Highlights
  - 7.5.1.1. Brazil Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.5.1.2. Brazil Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 7.5.1.3. Brazil Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 7.5.1.4. Brazil Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 7.5.1.5. Mexico Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.5.1.6. Mexico Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 7.5.1.7. Mexico Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 7.5.1.8. Mexico Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 7.5.1.9. Argentina Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.5.1.10. Argentina Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 7.5.1.11. Argentina Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 7.5.1.12. Argentina Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 7.5.1.13. Rest of Latin America Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 7.5.1.14. Rest of Latin America Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 7.5.1.15. Rest of Latin America Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 7.5.1.16. Rest of Latin America Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
- 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Antibodies Contract Manufacturing Market Outlook, 2018 - 2031

8.1. Middle East & Africa Antibodies Contract Manufacturing Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Monoclonal Antibodies
  - 8.1.1.2. Antibody Fragments
  - 8.1.1.3. Polyclonal Antibodies
8.2. Middle East & Africa Antibodies Contract Manufacturing Market Outlook, by Expression System, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Mammalian
  - 8.2.1.2. Microbial
    - 8.2.1.2.1. Bacteria
    - 8.2.1.2.2. Yeast
8.3. Middle East & Africa Antibodies Contract Manufacturing Market Outlook, by Company Size, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Small
  - 8.3.1.2. Mid-sized
  - 8.3.1.3. Large
  - 8.3.1.4. Very large
8.4. Middle East & Africa Antibodies Contract Manufacturing Market Outlook, by Scale of Operation, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. Preclinical
  - 8.4.1.2. Clinical
  - 8.4.1.3. Commercial
- 8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Middle East & Africa Antibodies Contract Manufacturing Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.5.1. Key Highlights
  - 8.5.1.1. GCC Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.5.1.2. GCC Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 8.5.1.3. GCC Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 8.5.1.4. GCC Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 8.5.1.5. South Africa Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.5.1.6. South Africa Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 8.5.1.7. South Africa Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 8.5.1.8. South Africa Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 8.5.1.9. Egypt Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.5.1.10. Egypt Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 8.5.1.11. Egypt Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 8.5.1.12. Egypt Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 8.5.1.13. Nigeria Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.5.1.14. Nigeria Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 8.5.1.15. Nigeria Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 8.5.1.16. Nigeria Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
  - 8.5.1.17. Rest of Middle East & Africa Antibodies Contract Manufacturing Market by Product, Value (US$ Bn), 2018 - 2031
  - 8.5.1.18. Rest of Middle East & Africa Antibodies Contract Manufacturing Market by Expression System, Value (US$ Bn), 2018 - 2031
  - 8.5.1.19. Rest of Middle East & Africa Antibodies Contract Manufacturing Market by Company Size, Value (US$ Bn), 2018 - 2031
  - 8.5.1.20. Rest of Middle East & Africa Antibodies Contract Manufacturing Market by Scale of Operation, Value (US$ Bn), 2018 - 2031
- 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Company Market Share Analysis, 2023
9.2. Competitive Dashboard
9.3. Company Profiles
- 9.3.1. AMRI
  - 9.3.1.1. Company Overview
  - 9.3.1.2. Product Portfolio
  - 9.3.1.3. Financial Overview
  - 9.3.1.4. Business Strategies and Development
- 9.3.2. AGC Biologics
  - 9.3.2.1. Company Overview
  - 9.3.2.2. Product Portfolio
  - 9.3.2.3. Financial Overview
  - 9.3.2.4. Business Strategies and Development
- 9.3.3. Aldevron
  - 9.3.3.1. Company Overview
  - 9.3.3.2. Product Portfolio
  - 9.3.3.3. Financial Overview
  - 9.3.3.4. Business Strategies and Development
- 9.3.4. Eurofins CDMO
  - 9.3.4.1. Company Overview
  - 9.3.4.2. Product Portfolio
  - 9.3.4.3. Financial Overview
  - 9.3.4.4. Business Strategies and Development
- 9.3.5. Boehringer Ingelheim BioXcellence
  - 9.3.5.1. Company Overview
  - 9.3.5.2. Product Portfolio
  - 9.3.5.3. Financial Overview
  - 9.3.5.4. Business Strategies and Development
- 9.3.6. FUJIFILM Diosynth Biotechnologies
  - 9.3.6.1. Company Overview
  - 9.3.6.2. Product Portfolio
  - 9.3.6.3. Financial Overview
  - 9.3.6.4. Business Strategies and Development
- 9.3.7. Emergent BioSolutions
  - 9.3.7.1. Company Overview
  - 9.3.7.2. Product Portfolio
  - 9.3.7.3. Financial Overview
  - 9.3.7.4. Business Strategies and Development
- 9.3.8. KBI Biopharma
  - 9.3.8.1. Company Overview
  - 9.3.8.2. Product Portfolio
  - 9.3.8.3. Financial Overview
  - 9.3.8.4. Business Strategies and Development
- 9.3.9. Pierre Fabre
  - 9.3.9.1. Company Overview
  - 9.3.9.2. Product Portfolio
  - 9.3.9.3. Financial Overview
  - 9.3.9.4. Business Strategies and Development
- 9.3.10. Lonza
  - 9.3.10.1. Company Overview
  - 9.3.10.2. Product Portfolio
  - 9.3.10.3. Financial Overview
  - 9.3.10.4. Business Strategies and Development
- 9.3.11. Novasep
  - 9.3.11.1. Company Overview
  - 9.3.11.2. Product Portfolio
  - 9.3.11.3. Financial Overview
  - 9.3.11.4. Business Strategies and Development
- 9.3.12. Nitto Avecia Pharma Services
  - 9.3.12.1. Company Overview
  - 9.3.12.2. Product Portfolio
  - 9.3.12.3. Financial Overview
  - 9.3.12.4. Business Strategies and Development

10. Appendix

10.1.Research Methodology
10.2.Report Assumptions
10.3.Acronyms and Abbreviations